Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Sells 19,084 Shares of Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris sold 19,084 shares of Tyra Biosciences stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $27.90, for a total value of $532,443.60. Following the sale, the chief executive officer now directly owns 1,355,927 shares of the company’s stock, valued at approximately $37,830,363.30. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Todd Harris also recently made the following trade(s):

• On Thursday, October 17th, Todd Harris sold 15,394 shares of Tyra Biosciences stock. The stock was sold at an average price of $25.85, for a total value of $397,934.90.
• On Tuesday, October 15th, Todd Harris sold 10,035 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.31, for a total value of $243,950.85.
• On Monday, September 30th, Todd Harris sold 500 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.00, for a total value of $12,000.00.
• On Wednesday, September 25th, Todd Harris sold 600 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.01, for a total value of $14,406.00.
• On Monday, September 23rd, Todd Harris sold 10,092 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.13, for a total value of $243,519.96.
• On Thursday, September 19th, Todd Harris sold 5,698 shares of Tyra Biosciences stock. The shares were sold at an average price of $24.31, for a total value of $138,518.38.

Tyra Biosciences Trading Down 0.7 %

NASDAQ TYRA opened at $28.16 on Wednesday. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of -16.66 and a beta of 1.01. Tyra Biosciences, Inc. has a twelve month low of $10.38 and a twelve month high of $28.81. The stock has a 50-day moving average of $22.62 and a 200 day moving average of $19.67.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. Equities analysts predict that Tyra Biosciences, Inc. will post -1.53 EPS for the current fiscal year.

Institutional Investors Weigh In On Tyra Biosciences

Large investors have recently bought and sold shares of the company. Oppenheimer & Co. Inc. purchased a new stake in Tyra Biosciences during the 1st quarter worth approximately $977,000. Vanguard Group Inc. increased its stake in Tyra Biosciences by 18.6% during the 1st quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock worth $14,757,000 after buying an additional 140,833 shares in the last quarter. American Century Companies Inc. increased its stake in Tyra Biosciences by 582.9% during the 2nd quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock worth $2,723,000 after buying an additional 145,346 shares in the last quarter. Perceptive Advisors LLC increased its stake in Tyra Biosciences by 50.5% during the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock worth $16,108,000 after buying an additional 338,208 shares in the last quarter. Finally, Ensign Peak Advisors Inc purchased a new stake in Tyra Biosciences during the 2nd quarter worth approximately $3,047,000. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Piper Sandler assumed coverage on Tyra Biosciences in a report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price objective for the company. HC Wainwright boosted their price objective on Tyra Biosciences from $25.00 to $30.00 and gave the company a “buy” rating in a report on Monday, October 7th. Wedbush reissued an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a report on Thursday, August 8th. Oppenheimer boosted their price objective on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday, September 19th. Finally, Bank of America raised Tyra Biosciences from a “neutral” rating to a “buy” rating and upped their price target for the stock from $22.00 to $31.00 in a report on Friday, October 18th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tyra Biosciences has a consensus rating of “Buy” and a consensus price target of $31.00.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.